Clinical trial · Observational
First Line Ovarian Cancer Treatment - Cohort Study
Non Interventional Study Dealing With the Use of Bevacizumab (Avastin®) in Patients With Epithelial Ovarian Cancer, Fallopian Tube or Primary Peritoneal and Treated in First-line Therapy
NCT01832415CI-TRIAL-00021417ENCOURAGEcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The French cooperative group GINECO proposes to implement an observational study to describe a real situation, in daily practice tolerance and methods of administration of bevacizumab (Avastin ®)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Epithelial Ovarian Cancer | Ovarian Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bevacizumab | Drug | Bevacizumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Use of bevacizumab (Avastin ®) - First-line ovarian cancer
- description
- Patient receiving bevacizumab in ovarian cancer first line treatment
- interventionNames
- Drug: Bevacizumab
Primary outcomes (1)
- measure
- Safety according to CTCAE v4.0 criteria
- timeFrame
- Patient will be followed dureing 36 months
- description
- To assess patient safety and the tolerance of bevacizumab andministered regarding the daily practice of the oncologist.
Secondary outcomes (6)
- measure
- Efficacy
- timeFrame
- Patient will be followed during 36 months
- description
- • Evaluate the efficacy of bevacizumab (Avastin ®) in terms of progression-free survival (PFS) .
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients aged 18 years and over, * Patients with an epithelial ovarian cancer, fallopian tube or peritoneal who will receive bevacizumab (Avastin ®) in first-line therapy * Patients should be informed of the study orally and should not have any objection their data to be processed. Exclusion Criteria: * Patient participation in a clinical trial * Patient non-affiliated to a social security scheme.
References
Publications (1)
- DERIVEDBerton D, Floquet A, Lescaut W, Baron G, Kaminsky MC, Toussaint P, Largillier R, Savoye AM, Alexandre J, Delbaldo C, Malaurie E, Barletta H, Bosacki C, Garnier-Tixidre C, Follana P, Laharie-Mineur H, Briac Levache C, Valenza B, Dechartres A, Mollon-Grange D, Selle F. Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients. Front Pharmacol. 2021 Sep 20;12:711813. doi: 10.3389/fphar.2021.711813. eCollection 2021. PMID 34616296